Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors

LESSONS LEARNED: Modified vaccinia Ankara‐Bavarian Nordic (MVA‐BN)‐Brachyury followed by fowlpox virus‐BN‐Brachyury was well tolerated upon administration to patients with advanced cancer. Sixty‐three percent of patients developed CD4+ and/or CD8+ T‐cell responses to brachyury after vaccination. BN‐...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Collins, Julie M., Donahue, Renee N., Tsai, Yo‐Ting, Manu, Michell, Palena, Claudia, Gatti‐Mays, Margaret E., Marté, Jennifer L., Madan, Ravi A., Karzai, Fatima, Heery, Christopher R., Strauss, Julius, Abdul‐Sater, Houssein, Cordes, Lisa, Schlom, Jeffrey, Gulley, James L., Bilusic, Marijo
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2019
Témata:
Clinical Trial Results
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7356719/
https://ncbi.nlm.nih.gov/pubmed/31876334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0932
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky